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Bromodomain and extra-terminal domain (BET)
family inhibitors offer an approach to treating hema-
tological malignancies. We used precision nuclear
run-on transcription sequencing (PRO-seq) to create
high-resolution maps of active RNA polymerases
across the genome in t(8;21) acute myeloid leukemia
(AML), as these polymerases are exceptionally sensi-
tive to BET inhibitors. PRO-seq identified over 1,400
genes showing impaired release of promoter-prox-
imal paused RNA polymerases, including the stem
cell factor receptor tyrosine kinase KIT that is
mutated in t(8;21) AML. PRO-seq also identified an
enhancer 30 to KIT. Chromosome conformation cap-
ture confirmed contacts between this enhancer and
the KIT promoter, while CRISPRi-mediated repres-
sion of this enhancer impaired cell growth. PRO-
seq also identified microRNAs, including MIR29C
and MIR29B2, that target the anti-apoptotic factor
MCL1 and were repressed by BET inhibitors. MCL1
protein was upregulated, and inhibition of BET pro-
teins sensitized t(8:21)-containing cells to MCL1 inhi-
bition, suggesting a potential mechanism of resis-
tance to BET-inhibitor-induced cell death.INTRODUCTION
The bromodomain and extra-terminal domain (BET) proteins
consist of four family members including BRD2, BRD3, BRD4,
and BRDT (Wu and Chiang, 2007). These BET proteins bind toCell Re
This is an open access article undthe acetylated lysines of histone tails and other non-histone nu-
clear proteins through two conserved N-terminal bromodomains
(Dey et al., 2003; Filippakopoulos et al., 2012; Wu and Chiang,
2007; Zhang et al., 2013). BET proteins are typically associated
with enhancers and bind to positive transcription elongation
factor b (P-TEFb, which contains cyclin T and CDK9), which is
critical for the release of promoter-proximal paused RNA poly-
merases into productive elongation (Chapuy et al., 2013; Liao
et al., 1995; Love´n et al., 2013; Marshall and Price, 1995; Peng
et al., 1998; Yang et al., 2005). The binding of BRD4 appears
to activate P-TEFb by releasing it from the inhibitory HEXIM1-
7SK complex (Bartholomeeusen et al., 2012; Jang et al., 2005;
Liu et al., 2014). This stimulates CDK9-dependent phosphoryla-
tion of the C-terminal domain of RNA polymerase II (RNAPII) as
well as negative elongation complexes, DSIF and NELF, which
causes dissociation of NELF and switches DSIF into a positive
elongation factor, to trigger RNAPII elongation (Wada et al.,
1998a, 1998b; Yamaguchi et al., 1999). Small molecule inhibitors
of BET proteins, such as JQ1, I-BET, and MS417, mimic the
acetylated lysine moiety and competitively bind to the two bro-
modomains (BD1 and BD2) to displace BET proteins from chro-
matin (Filippakopoulos et al., 2010; Nicodeme et al., 2010; Zhang
et al., 2012a). BET inhibitors show efficacy in preclinical models
of acute myeloid leukemia (AML), multiple myeloma, and certain
types of lymphoma as well as other cancer types (Chapuy et al.,
2013; Dawson et al., 2011; Delmore et al., 2011; Feng et al.,
2014; Filippakopoulos et al., 2010; Lockwood et al., 2012; Ott
et al., 2012; Zuber et al., 2011).
Consistent with BRD4 interacting with P-TEFb, gene expres-
sion studies showed that BET inhibitors induced downregulation
of mRNAs including key oncogenes important for cell cycle pro-
gression, such as MYC and E2F1, genes that control cell death
such as BCL2, as well as lineage-specific oncogenes such as
BCL6 (Chapuy et al., 2013; Dawson et al., 2011; Delmore et al.,ports 16, 2003–2016, August 16, 2016 ª 2016 The Author(s). 2003
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2011; Ott et al., 2012; Zuber et al., 2011). Genomic binding
studies revealed that these genes are associated with BRD4-
enriched enhancers that are essential for the efficient transcription
of these genes. The so-called ‘‘super-enhancers,’’ clusters of en-
hancers, are particularly sensitive toBET inhibitors causing the se-
lective transcriptional repression of those super-enhancer-driven
genes (Chapuy et al., 2013; Love´n et al., 2013). However, as a
global chromatin reader, BRD4 is also highly enriched at active
promoters, and the mechanism of action of BET inhibitors has
been inferred from chromatin immunoprecipitation sequencing
(ChIP-seq) studies showing less RNAPII associated with the
body of the gene after treatment of BET inhibitors, but these
ChIP studies have relatively low resolution and sensitivity, and
they do not provide directional information (i.e., the direction poly-
merase is transcribing) (Love´n et al., 2013; Zhang et al., 2012b).
In these early studies of BET inhibitors, the t(8;21) cell line
Kasumi-1 showed an exceptional response to these compounds
with 2- to 5-fold higher sensitivity than other leukemia types
(Zuber et al., 2011). The t(8,21) is one of the most common chro-
mosomal translocations in AML and yields an immature myeloid
leukemia (M2 subtype) that not only expresses the stem cell fac-
tor receptor, KIT, but up to 48% of these leukemia also contain
activating mutations of KIT (Gao et al., 2015; Park et al., 2011;
Paschka et al., 2006; Wang et al., 2005). In fact, KIT mutation
is associated with poor outcome in t(8;21) AML and is often
observed in relapsed t(8;21) patients (Park et al., 2011; Paschka
et al., 2006; Schnittger et al., 2006). Moreover, these cells are
sensitive to KIT tyrosine kinase inhibitors, indicating that mutant
KIT is an oncogenic mutation in t(8;21) AML (Wang et al., 2005).
In total, KIT is activated by point mutation and/or amplified in up
to 8% of AML (Forbes et al., 2015; Wheeler et al., 2013). More-
over, KIT is amplified in multiple tumor types including 16% of
prostate cancers, 10%of glioblastoma, and 4%–5%of lung can-
cer (The Cancer Genome Atlas cBioPortal for Cancer Genomics)
(Barbieri et al., 2012; Brennan et al., 2013; Cancer Genome Atlas
Research Network, 2008, 2012; Cerami et al., 2012; Gao et al.,
2013).
We used high-resolution mapping of active RNA polymerases
to define the mechanism of transcriptional control by BET inhib-
itors in t(8;21) AML and find that in 64% of the affected genes,
BET inhibitors increased promoter-proximal RNA polymerase
pausing. We also defined the effects of the drugs on enhancer-
templated RNA (eRNA) and microRNA production. One of
the genes suppressed was KIT, which could be a key target
of BET inhibitors in 80% of AML. Conversely, BET inhibitors
transcriptionally induced the expression of the anti-apoptotic
BCL2-family member MCL1, while suppressing microRNAs
that regulate the production ofMCL1, such that the combined ef-
fect was rapid and sustained induction of MCL1. MCL1 expres-
sion is associated with drug resistance in multiple myeloma and
is upregulated during leukemic relapse (Derenne et al., 2002;
Kaufmann et al., 1998; Wuille`me-Toumi et al., 2005). While treat-
ment of t(8;21) cells with a selective MCL1 inhibitor had little
effect, pretreatment with a BET inhibitor caused a concomitant
loss ofBCL2 and induction of MCL1, which sensitized these cells
to MCL1 inhibition and apoptosis. Thus, BET inhibitors may be
extremely useful in AML containing KIT driver mutations, and
combination therapy with an MCL1 inhibitor may be beneficial.2004 Cell Reports 16, 2003–2016, August 16, 2016Moreover, changes in KIT cell surface expression may be useful
in monitoring the response to BET inhibitors in clinical trials.
RESULTS
BET Inhibitors Cause Promoter-Proximal Pausing of
RNA Polymerases
Early studies identified AML as especially sensitive to inhibitors
of BET family members, and the t(8;21) cell line Kasumi-1 ap-
peared to be the most sensitive cell line (Zuber et al., 2011).
We extended these results to the t(8;21)-containing SKNO-1
cell line that requires granulocyte-macrophage colony stimu-
lating factor (GM-CSF) for growth (Matozaki et al., 1995) and
found that Kasumi-1 and SKNO-1 cells were more sensitive
than MOLM13 and MV4-11 when using alamarBlue assays to
assess cell metabolism as a surrogate for cell proliferation (Fig-
ure S1A; Y.Z., T.M. Heaster, K.R.S., M.C. Skala, M.R.S., and
S.W.H., unpublished data). We also extended this work to a
more potent BET inhibitor, MS417 (Zhang et al., 2012a), which
was 2- to 3-fold more efficacious than JQ1 at restricting
Kasumi-1 cell growth (Figure S1A). Surprisingly, when we tested
whether BET inhibitors triggered apoptosis in Kasumi-1 cells,
both JQ1 and MS417 only had a minor effect in the first
24–48 hr, whereas SKNO-1 showed more cell death at 48 hr
(Y.Z., T.M. Heaster, K.R.S., M.C. Skala, M.R.S., and S.W.H.,
unpublished data; see Figure 7F). Thus, while t(8;21)-containing
cells were very sensitive, BET inhibitors inhibited cell prolifera-
tion without causing widespread apoptosis.
Kasumi-1 cells are an excellent model of t(8;21) leukemia in
terms of epigenetic and transcriptional control, as direct com-
parison with primary patient samples yielded similar epige-
netic marks and transcription factor (TF) occupancy (Ptasinska
et al., 2012, 2014). Because Kasumi-1 cells are also extremely
sensitive to BET inhibitors, we used precision nuclear run-on
transcription coupled with deep sequencing (PRO-seq) to
probe the mechanistic basis for this exceptional response to
BET inhibitors and to gain insights into the mechanism of action
of these compounds (Kwak et al., 2013). PRO-seq provides both
directional information and near nucleotide resolution of the
genome-wide positions of actively engaged RNA polymerases
and is the ideal method to test the proposed mechanism of
action of BRD2, BRD3, and BRD4, which are thought to stimu-
late paused RNA polymerase to elongate via association with
P-TEFb (Jang et al., 2005; Yang et al., 2005).
We reasoned that the regulation of nascent transcription
should be detectable within the first 1–3 hr after drug treatment
and that these early times should reflect the direct transcriptional
effects of BET inhibitors, rather than secondary or compensatory
effects that might occur 4–8 hr after addition of the drug. There-
fore, we initially treated cells with JQ1 or MS417 for 1 and 3 hr,
and PRO-seq was performed. At the same time, RNA was
collected for RNA-seq analysis to compare the cytoplasmic
pools of mRNA with the effects on transcription. The effects of
BET inhibitors on transcriptionally engaged RNA polymerases
were calculated using the read densities in the promoter-prox-
imal region versus the gene body, and a ‘‘pausing index’’ was
defined as the ratio of promoter-proximal density divided by
gene body density (Core et al., 2008; Kwak et al., 2013; Min
et al., 2011). Polymerases near the transcription start site (TSS),
but moving away from the gene body (i.e., divergent transcripts),
were excluded. Importantly, such pausing indices can be
compared between samples without normalization, because it
measures the relative polymerase content within the same
gene (Figure 1A). Since JQ1 and MS417 are different inhibitors
targeting the same BET proteins, these two samples were
treated as biological replicates, and only genes identified by
both inhibitors were used for further analyses.
By comparing pausing indices between control and BET-
inhibitor-treated samples, we identified 1,905 RefSeq genes
showing an increased pausing index 1 hr after treatment, while
only 234 genes showed a decreased pausing index (Figures
1B and 1C). The high percentage of overlap between JQ1- and
MS417-treated samples verified the accuracy of these studies.
When the read counts of the 1,905 genes showing an increase
in pausing index 1 hr after BET inhibitor treatment were plotted
relative to the TSS (Figure 1D), most of these genes showed a
gain of RNA polymerase near the TSS (e.g., MYC, Figures S1C
and 1D, upper bracket). However, there was a small group of
genes that showed increased levels of promoter-proximal and
gene body transcription (yet the net effect was a gain of pausing
index; Figure 1D, bottom bracket), suggesting that BET proteins
may also play a repressive role in transcription for these genes
(e.g., MCL1, Figure S1C). As expected, many genes identified
1 hr after treatment showed an even greater level of pausing at
3 hr after treatment, and more genes were identified with
increased pausing indices 3 hr after treatment, which can be
classified as delayed-early genes (Figures 1B and 1C). This could
be due to a delayed action of BET inhibitors, but MYC protein
levels were reduced by about 50% by 3 hr after treatment (Fig-
ure S1B), so we were likely assessing indirect or compensatory
changes at this time point.
A smaller number of genes (9%) displayed reduced levels
of both promoter-proximal and gene body read densities (Fig-
ure1D,middlebracket), butwitha larger lossof genebodydensity
such that these genes were captured in our informatics analysis
(e.g.,BCL2, Figures 1G andS1C), which could be due to changes
in transcription initiation. Toexamine this aspect ofBET regulation
inmore detail, wedirectly compared normalizedRNApolymerase
gene body densities and found 1,033 genes repressed and 346
genes activated by BET inhibitors (Figure 1E, left panels). Among
the 1,033 repressed genes, 454 genes showed significantly
increased pausing index, which was captured by the pausing in-
dex comparison analysis (Figure 1E, right) and is indicative of an
inhibition of the release of RNAPII to productive elongation. Inter-
estingly, 575 genes showed no change of pausing index and
4 genes showed decreased pausing index, suggesting that BET
inhibitors also affect transcription initiation.
To better trace the kinetics of RNA polymerase elongation
after BET inhibitor treatment, we performed PRO-seq with JQ1
treatment for 15 and 30 min and confirmed that our identified
target genes were quickly affected by JQ1 at the pause release
and/or initiation stages (Figures S1D–S1F). When longer genes
were plotted, the gap downstream of the promoter-proximal
site revealed the block of paused RNAPII release to productive
elongation, which lengthened with time (Figures 1F and 1G).
This indicates that BET inhibitors alter pausing release withoutaffecting the RNA polymerases that have already passed the
pausing checkpoint.
We also performed RNA-seq experiments in parallel to better
understand the sensitivity of PRO-seq at detecting immediate
transcriptional changes (Figures S1G and S1H). 1 hr after treat-
ment, only 187 genes were significantly downregulated at least
1.5-fold in the RNA-seq dataset, while 100 genes were upregu-
lated (Figure S1G). Thus, PRO-seq detected over 5-fold more
genes showing repressed gene body transcription (1,033 versus
187). Gene ontology analyses indicated that seven TFs that regu-
late cell cycle progression and cell proliferation were affected in
both PRO-seq and RNA-seq (Figures S1I and S1J), suggesting
that by 3 hr we likely detected indirect effects of the de-regula-
tion of these TFs. Indeed, by 3 hr 1,049 mRNAs were downre-
gulated at least 1.5-fold, but only 494 of these showed a direct
transcriptional effect of BET inhibition by PRO-seq (Figure S1I).
Of note, BRD3 was expressed at low levels so BET inhibitors
act only through BRD2 and BRD4 in Kasumi-1 cells. Taken
together, PRO-seq enabled us to identify the transcriptional
effects of BET inhibitors within the first hour of treatment, ruling
outmost secondary effects from longer treatment and post-tran-
scriptional regulation.
KIT Is Targeted by BET Inhibitors
In our gene ontology analysis, stress response geneswere among
the most robustly affected gene clusters (Figure S2A), which is
consistent with this group of genes being regulated by paused
RNAPII release to productive elongation (Lis et al., 2000; Mahat
et al., 2016). In addition, BET inhibitors downregulated genes,
including those controlling metabolism (e.g., oxidative phosphor-
ylation, RNA transport, Ribosome biogenesis, and mitochondrial
diseases; FigureS2B). This groupof genesmayhavebeenmissed
by RNA-seq at early time points as most of these genes have
abundant mature mRNA. TF enrichment analyses identified bind-
ing motifs in these BET inhibitor-regulated genes for MYC, E2F,
IRF, NFMUE1, ELK1, and HIF1 (Figure S2C).
We also noted a large number of genes with increased pausing
indices at both time points that are important for hematopoietic
malignancies such as DNMT3A, BCL6, IKZF1, ATRX, ETV6,
LMO2, CSF3R, PAX5, and TET2 (Figure S2A). In the context of
the t(8;21), a gene that was of particular interest was the stem
cell factor receptor tyrosine kinase, KIT, which was quickly
repressed by BET inhibitors as detected by PRO-seq (Figures
1G, bottom, and 2A). KIT is expressed in 80% of AML and is acti-
vated by an N822K mutation in both Kasumi-1 and SKNO-1 cells
(Becker et al., 2008; Ikeda et al., 1991; Larizza et al., 2005). Also,
this mutant KIT allele is amplified in Kasumi-1 cells and confers
sensitivity to the tyrosine kinase inhibitor imatinib (Larizza et al.,
2005; Wang et al., 2005). Consistent with the PRO-seq analysis,
RNA-seq detected a 50% decrease in KIT mRNA 3 hr after
BET inhibitor treatment (Figure 2B). KIT cell surface expression
was reduced by JQ1 in Kasumi-1 and SKNO-1 cells beginning
at 9 hr after JQ1 treatment (not shown) with more pronounced
loss by 24 hr (Figures 2C and 2D). By contrast, the t(8;21) fusion
protein RUNX1-ETOwas onlymodestly affected byBET inhibitors
(Figure S2D). As expected, treatment of Kasumi-1 cells with the
tyrosine kinase inhibitor imatinib also reduced cell growth with
an EC50 at 400 nM (Figure 2E, arrow). Combined treatmentCell Reports 16, 2003–2016, August 16, 2016 2005
Figure 1. PRO-Seq Analysis of Kasumi-1 Cells Treated with BET Inhibitors for 1 and 3 hr
(A) Illustration of the calculation of RNA polymerase promoter-proximal pausing. TSS, transcription start site; TTS, transcription termination site; pp, promoter-
proximal; gb, gene body.
(B) Venn diagrams show the number of genes displaying an increase (top) or decrease (bottom) of polymerase pausing 1 hr (left) or 3 hr (right) after treatment with
250 nM JQ1 or 125 nM MS417.
(C) Heatmaps displaying the genes identified by both JQ1 and MS417 treatment showing an increase or decrease of polymerase pausing. Genes were ranked
based on log2-transformed fold change of pausing indices.
(D) Heatmaps displaying log2-transformed fold change (log2FC) of read counts in 200-bp bins ± 5 kb around the TSSs of the 1,905 genes that show an increase of
pausing index after BET inhibitor treatment for 1 hr.
(E) Heatmaps displaying log2-transformed fold change of read counts in 200-bp bins ± 5 kb around the TSSs of the genes that were up- or downregulated in the
gene body by BET inhibitor treatment for 1 hr. Genes were ranked based on log2-transformed fold change of RNA polymerase in the promoter-proximal region.
(F) PRO-seq was performed using 250 nM JQ1 at 15- and 30-min time points. Normalized average counts of RNA polymerase were plotted 10 kb to +150 kb
from TSSs with 3-kb bins for the genes downregulated by BET inhibitors in the gene body and longer than 150 kb.
(G) PRO-seq IGV BedGraph screenshots of BCL2 (top) and KIT (bottom) 15 and 30 min after JQ1 treatment. The arrows indicate the interface when RNAPII
encountered a block of transcription elongation.
See also Figure S1.
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Figure 2. KIT Is Targeted by BET Inhibitors in t(8;21) AML Cell Lines
(A) PRO-seq IGV BedGraph screenshots of KIT at 1 hr after BET inhibitor
treatment. Double hatchmarks indicate that the actual peak size of the paused
promoter-proximal RNA polymerases is higher and the numbers are read
densities (read per base pair) of polymerase peaks.
(B) Mature mRNA levels were monitored using RNA-seq in the same samples
when performing PRO-seq experiments. Read quantification displays an
about 50% reduction of KIT mRNA expression 3 hr after BET inhibitor
treatment.
(C and D) Kasumi-1 (C) and SKNO-1 (D) cells were treated with 250 nM JQ1 for
24, 48, and 72 hr and KIT cell surface expression was quantitatively assessed
by flow cytometry. Representative plots are shown (n = 3). Shaded area rep-
resents DMSO, and white plots represent JQ1.
(E) Kasumi-1 cells were treated with combined increasing doses of JQ1 and
imatinib (Ima) for 3 days, and cell growth wasmeasured by alamarBlue assays.
See also Figure S2.with increasing doses of JQ1 and imatinib enhanced the inhibition
of cell growth, suggesting that repression ofKIT contributes to the
effect of BET inhibitors, but that loss of KIT is not the solemediator
of this effect (Figure 2E). Thus, BET inhibitors turn off not onlyMYC
but also drivers of leukemogenesis such as mutant KIT, which
likely contributes to the sensitivity of t(8;21)-containing cells to
BET inhibitors.
BET Inhibitors Affect eRNA Transcription
BET family members are typically associated with enhancers
and are displaced from chromatin by BET inhibitors, whichis commonly associated with enhancer inactivation (Chapuy
et al., 2013; Love´n et al., 2013). Because active enhancers pro-
duce 50-capped eRNAs and the activation of eRNAs correlates
with increased transcription of neighboring genes (Andersson
et al., 2014; Core et al., 2014), PRO-seq data allow identification
of transcriptionally active enhancers, whereas traditional ChIP-
seq experiments of histonemodifications (e.g., H3K27ac) cannot
distinguish active from inactive enhancers.
We first assessed the myeloid-specific MYC super-enhancer
(Shi et al., 2013). Consistent with the ChIP-seq data, divergent
transcription identified specific transcriptional start sites asso-
ciated with the five previously identified ‘‘sub-enhancers’’ (Fig-
ure 3A; Figure S3A). In addition, we identified a sixth enhancer
in this region containing a well-defined transcriptional start site
(E6 in Figures 3A and S3A). We also identified a previously unrec-
ognized potential long eRNA being expressed from E5 (Figures
3A, S3A, and S3B). Importantly, normalized read densities
were substantially reduced by BET inhibitors, especially within
the second, fifth, and sixth enhancers (Figure 3B), which is
consistent with MYC being regulated by this super-enhancer in
myeloid malignancies.
Next, we performed ChIP-exonuclease sequencing (ChIP-
exo) for H3K27ac and analyzed the PRO-seq data in com-
parison with ChIP-exo data for H3K27ac in Kasumi-1 cells to
identify enhancers. Only intergenic enhancers were identified
in this study, as transcripts derived from intragenic enhancers
are difficult to distinguish from gene transcription. With a
method modified from a previously published algorithm (Hah
et al., 2013), we identified 2,631 active intergenic enhancers,
which were also marked with H3K27ac (Figure 3C). When
compared with H3K27ac marked intergenic regions, PRO-seq
was able to identify weak enhancers with higher sensitivity,
and it distinguished active enhancers from open chromatin
marked by H3K27ac (Figure S3C). Using a 1.5-fold change as
a cutoff, 613 enhancers had fewer RNA polymerases associ-
ated after treatment with either JQ1 or MS417, while only 93 en-
hancers were activated (Figure 3D). With a simplified proximity
rule (Love´n et al., 2013), which assigned enhancers to their
closest active genes within a 50-kb window, we identified 208
active genes that were associated with repressed enhancers
(Figure 3E, left), and their pausing indices were significantly
increased by BET inhibitors (Figure 3F).
Previous enhancer-gene association studies relied on mature
mRNA levels, while PRO-seq can directly measure transcrip-
tional changes using gene body read counts. We selected tran-
scriptionally active intergenic enhancers that are marked by
overlapping H3K27ac ChIP-exo peaks, BRD4 ChIP-seq peaks
previously reported in myeloid cells, and PRO-seq defined en-
hancers (Dawson et al., 2014; Gro¨schel et al., 2014; Poss
et al., 2016). Although both BRD2 and BRD4 are highly ex-
pressed in Kasumi-1 cells (data not shown), we focused on
BRD4 as it best correlates with JQ1 genomic target sites (Anders
et al., 2014). Next, we identified so-called super-enhancers that
have multiple H3K27ac peaks (Figure S3D) and examined their
function on regulating neighboring gene transcriptional changes.
We consistently found that genes associated with super-en-
hancers showed greater reduction of transcription as measured
by PRO-seq gene body read count (Figure S3E).Cell Reports 16, 2003–2016, August 16, 2016 2007
Figure 3. PRO-Seq Identification of Enhancers and Long eRNA Affected by BET Inhibitors
(A and B)MYC super-enhancer, which consists of six sub-enhancers (E1–E6), is located 1.8Mb downstream of theMYC gene (A, top). Gray arrows indicate eRNA
transcription initiated from E5, which was repressed by BET inhibitors (A, bottom). Quantification of eRNA synthesis from the six sub-enhancers, showing that
BET inhibitors affect eRNA transcription 1 hr after drug addition (B).
(C) PRO-seq called intergenic enhancers showing an enrichment of H3K27ac. PRO-seq double peaks around the center of enhancers indicate divergent
transcription.
(D) Venn diagrams showing the number of enhancers repressed or activated at 1 hr after BET inhibitor treatment.
(legend continued on next page)
2008 Cell Reports 16, 2003–2016, August 16, 2016
Figure 4. PRO-Seq Identifies a KIT Enhancer
(A) IGV BedGraph screenshots of the enhancer 30 to
KIT. Top three PRO-seq gene tracks display
three sub-enhancers (E1–E3) identified by bidirec-
tional transcription. Green shadows with arrows
highlight the eRNA transcribed from E1 and
repressed by BET inhibitors, which is confirmed by
RNA-seq (middle tracks). The bottom ChIP-exo
gene track shows the enrichment of H3K27ac
at the transcription initiation sites of the three
sub-enhancers.
(B) ChIP assays show BRD4 enrichment around the
transcription initiation sites of the three sub-en-
hancers E1–E3, which was dramatically reduced
1 hr after BET inhibitor treatment. Neg-ctrl repre-
sents a negative control region that shows no tran-
scriptional activity determined by PRO-seq. Data
are mean ± SEM (n = 3).
(C) 3C experiments were performed with an anchor
point fixed at the KIT promoter. Transcriptionally
inactive regions up- (UP) and downstream (DN) of
the KIT gene were used as negative controls.
All ligation efficiencies were normalized to digested
and religated BAC templates. Data are mean ± SE
(n = 3).
(D and E) The KIT downstream sub-enhancers
were repressed by CRISPRi with individual
sgRNAs targeting E1, E2 (two different sgRNAs
E2.1 and E2.2 are shown), and E3. KIT cell
surface expression was analyzed by flow cy-
tometry 2 and 3 days after infection. Bar graphs
show the quantification of cells expressing low
levels of KIT. Data are mean ± SE (n = 3) (D).
The cells with low KIT expression were pulsed
with BrdU on day 3 for cell cycle analysis.
Representative plots on the left display no
BrdU incorporation (BrdU-neg) in the KIT-low cell
population (red boxes), which is quantified
and shown in bar graphs on the right. Data are
mean ± SE (n = 3) (E).
See also Figure S4.We also found 70 PRO-seq defined downregulated enhancers
spanning larger genomic regions (>10 kb), and 47 of these
enhancers contain at least 2 sub-enhancers characterized by
bi-directional transcription. A major advantage of PRO-seq is
that it allows the identification of eRNAs, and we noted that 62
of the 70 large enhancers transcribed at least 1 long eRNA
(6 kb46 kb) from their corresponding initiation sites (e.g., an in-
tergenic enhancer region transcribing long eRNAs is shown in
Figure S3F). BET inhibitors reduced the release of RNA polymer-(E) Repressed enhancers associated with (left) or without (right) a proximal activ
(F) Active genes associated with repressed enhancers display an increase of pau
using one-sided Wilcoxon signed-rank test.
(G) Average RNA polymerase levels within the 62 long eRNAs that are affected b
Arrows indicate the peaks of RNA polymerases.
(H) Box plots showing pausing indices of the 62 long eRNAs upon BET inhibitor tre
See also Figure S3.ases into the eRNA body, causing an increase in the pausing in-
dex for these eRNAs (Figures 3G and 3H).
PRO-Seq Identifies a KIT Enhancer 30 to KIT
Importantly, this analysis identified a region 50 kb 30 to the
KIT locus containing three actively transcribed regions and a
long eRNA, which was dramatically affected by BET inhibitors
(Figure 4A, gray arrows in the top three tracks). This eRNA was
also captured by our RNA-seq analysis using polyA enrichede gene.
sing index at 1 hr after treatment with BET inhibitors. p values were calculated
y BET inhibitor treatment, showing the loss of eRNA transcription elongation.
atment. p values were calculated using one-sidedWilcoxon Signed-Rank test.
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Figure 5. PRO-seq Analysis of Primary AML
Patient Cells
(A and B) Primary AML patient cells were treated
with DMSO or 250 nM JQ1 for 1 hr. PRO-seq IGV
BedGraph screenshots show a repressive effect of
JQ1 on KIT transcription (A) and its downstream
enhancer and eRNA (B).
(C–E) Analysis of the eRNA transcribed from the
KIT enhancer in nine primary AML patient samples
treated with DMSO or 250 nM JQ1. Total RNA
was collected 3 hr after JQ1 treatment to detect
transcriptional changes of KIT mRNA (D) and the
30 eRNA (E). Transcription of eRNA was determined
by two pairs of primers targeting the short form of
eRNA that can be detected by both PRO-seq and
RNA-seq (E, top; also refer to Figure S4A). KIT cell
surface expression was measured by flow cy-
tometry 48 hr after JQ1 treatment (C), and repre-
sentative KIT-positive and -negative AML patient
cells are displayed.
See also Figure S5.RNA and RT-PCR using primers throughout the length of this
eRNA (Figure 4A, gray arrows in the middle three tracks; Fig-
ure S4A). Interestingly, the eRNA detected by RNA-seq was
shorter (12 kb) than the transcribed region, and its 30 end is fol-
lowed by an accumulation of RNAPII in the PRO-seq analysis,
which is commonly observed 30 of the transcription cleavage
and polyadenylation site associated with RNA processing (Fig-
ure 4A) (Core et al., 2008; Glover-Cutter et al., 2008). The three
sub-enhancers (identified by divergent transcription) were en-
riched with H3K27ac in ChIP-exo analysis, which is commonly
used as histone markers for active enhancers (Figure 4A, bot-
tom track). Moreover, ChIP assays revealed BRD4 binding
around the transcription initiation sites of the three sub-en-
hancers (E1, E2, and E3), which was almost completely dis-
rupted 1 hr after BET inhibitor treatment (Figure 4B).
To validate that this region is a KIT enhancer, we performed
chromosome conformation capture (3C) experiments and
showed that E2 interacts with the KIT promoter (Figure 4C). This
interaction was not affected by JQ1 treatment, suggesting that
BET proteins are not required for chromatin looping. We next
used a CRISPRi system to repress the individual sub-enhancers,
in which a deactivated Cas9 was fused to a transcriptional re-
pression domain KRAB and can be directed to a genomic region
targeted by sgRNA. Multiple sgRNAs were designed for each
sub-enhancer, and only repressing E2 reduced KIT expression
(Figures 4D and S4B). Moreover, the cells with reduced KIT cell
surface expression showed impaired cell cycle progression, as2010 Cell Reports 16, 2003–2016, August 16, 2016no DNA synthesis was detected by BrdU
incorporation assays (Figure 4E). Thus, E2
is the predominant enhancer region regu-
lating KIT transcription, which is important
for cell cycle progression.
PRO-Seq Analysis of Primary AML
Patient Cells
Consistent with KIT being expressed in he-
matopoietic stem and progenitor cells andAML cells, the transcription of KIT and its putative enhancer was
only detected in Kasumi-1 cells and was not detectable in other
available PRO-seq datasets from lymphoid tissues (Figure S5A),
re-enforcing the usefulness of BET inhibitors in KIT-positive
AMLs. Therefore, we extended our findings to a primary KIT-
positive AML patient sample for which ample material was avail-
able (PRO-seq requires 20 million cells). PRO-seq analysis
confirmed that JQ1 impaired transcription elongation in patient
cells, with 2,680 genes showing increased pausing indices, while
only 736 genes showed decreased pausing indices (Figure S5B).
Among the 3,416 affected genes, 58% of them were also signif-
icantly changed by BET inhibitors in Kasumi-1 cells. Consistent
with our findings in Kasumi-1 cells, geneswith increased pausing
indices were important for hematopoietic diseases and cell sur-
vival and proliferation (Figures 5A and S5C).Wewere also able to
detect the six enhancers that regulateMYC (Figure S5D) and the
three enhancers that regulate KIT (Figure 5B). Moreover, tran-
scription elongation of the KIT eRNA was inhibited by JQ1 (Fig-
ure 5B, blue arrow).
Next, we tested whether BET inhibitor treatment affects KIT
expression in primary AML patient samples. Nine primary AML
samples were treated ex vivo with JQ1 (samples 1, 2, 3, 4, 5,
and 7were KIT positive, while samples 6, 8, and 9were KIT nega-
tive) (Figure 6C). Among the KIT-positive AML samples, five
(samples 1, 2, 3, 4, and 7) expressed significant amounts of
KIT mRNA and its 30 eRNA, which was dramatically downregu-
lated by JQ1 (Figures 6D and 6E) with concurrent loss of cell
Figure 6. BET Inhibitors SuppressMicroRNAs
Targeting MCL1
(A) Heatmaps on the left display the pri-microRNAs
identified by both JQ1 and MS417 treatment
showing an increase or decrease of RNA polymerase
pausing index. Each cell represents log2-trans-
formed fold change of pausing indices and they are
ranked based on fold change of pri-microRNA body
densities. A zoomed view of the top 20% most
changed pri-microRNAs both 1 and 3 hr after BET
inhibitor addition (27 with increased pausing indices
and 2 with decreased pausing indices) is shown on
the right, which displays pri-microRNA body den-
sities. MicroRNAs transcribed from individual pri-
microRNAs are listed on the side.
(B andC)PRO-seq IGVBedGraph screenshots of pri-
microRNAs transcribing MIR223 (B) and MIR29C;
MIR29B2 (C). Gray boxes indicate pri-microRNA
TSSs defined by divergent transcription.
(D and E) Kasumi-1 cells were treated with DMSO,
250 nM JQ1, and 125 nM MS417 for 1 hr. ChIP as-
says show the enrichment of BRD4 binding around
the TTSs of MIR223 (D) and MIR29C-MIR29B2 (E)
pri-microRNAs, which was dramatically reduced by
BET inhibitors. Neg-ctrl represents a negative control
region, which shows no transcriptional activity
determined by PRO-seq data. Data are mean ± SEM
(n = 3).
See also Figure S6.surface KIT expression (Figure 6C). By contrast, the KIT-negative
samples (e.g., samples 6 and 8) barely expressed any KITmRNA
or its 30 eRNA (Figures 6D and 6E). Although samples 5 and 10
also expressed detectable KIT mRNA and their mRNA levels
were reduced by JQ1, we could not detect any change of KIT
cell surface expression for sample 5, and sample 10 failed to
express KIT on its cell membrane, suggesting that non-tran-
scriptional mechanisms also contribute to regulating KIT expres-
sion in some cases.
Suppression of MicroRNAs Enhance MCL1 Induction by
BET Inhibitors
MicroRNAs are small non-coding RNAs (22 nucleotides) that
regulate gene expression by affecting mRNA stability and trans-
lation (Ha and Kim, 2014). About 60% of microRNAs are co-tran-Cell Rescribed from protein-coding gene,s and
another 40% of them are localized to
intergenic regions. MicroRNAs are initially
transcribed as long primary microRNAs
(pri-microRNAs) and undergo sequential
processing steps during maturation (Ha
and Kim, 2014). While the functional roles
of microRNAs have been extensively char-
acterized, it has been challenging to define
their transcriptional regulation without
accurately predicting the TSSs of their
pri-microRNAs. By examining all transcrip-
tionally engaged RNA polymerases, PRO-
seq allowed us to identify 787 pri-micro-
RNAs (206 intergenic and 581 intragenicpri-microRNAs) expressed in Kasumi-1 cells. By 1 hr after BET
inhibitor addition, 126 pri-microRNAs showed an increase of
pausing index, while only 15 pri-microRNAs showed a decrease
of pausing index (Figure 6A, left). 3 hr after BET inhibitor addition,
189 pri-microRNAs were detected with an increased pausing in-
dex and 7 pri-microRNAs showed a decreased pausing index
(Figure 6A, left). Among the 126 pri-microRNAs showing an in-
crease of pausing index after 1 hr of treatment, the highly ex-
pressed pri-microRNA for MIR223, which targets E2F1, was
the most affected by BET inhibitors (Figures 6A, right, 6B, and
S6). Moreover, the pri-microRNA of MIR29B2 and MIR29C that
target MCL1 was among the top 20% of the pri-microRNAs
with gain of pausing (Figures 6A, right, 6C, and S6). ChIP assays
further revealed BRD4 binding at the TSSs of the pri-microRNAs
of MIR223 and MIR29B2-MIR29C, which was dramaticallyports 16, 2003–2016, August 16, 2016 2011
Figure 7. BET Inhibitors Sensitize Kasumi-1
Cells to MCL1 Inhibition
(A and B) PRO-seq IGV BedGraph screenshots
display reduced transcription of MIR29B2 and
MIR29C and activated MCL1 transcription after
JQ1 treatment in primary AML patient cells.
(C and D) Time-course examination of E2F1 (C)
and MCL1 (D) protein levels in Kasumi-1 cells
treated with DMSO (D) and 250 nM JQ1. a-tubulin
was used as loading control. The downregulation
of a-tubulin at 48 and 72 hr reflects an effect of cell
cycle arrest by long-term treatment of BET in-
hibitors.
(E) SKNO-1 cells were treated 250 nM JQ1, and
MOLM13 and MV4-11 cells were treated with
500 nM JQ1. DMSO (D) served as control. MCL1
protein levels were assessed by western blot.
(F) Kasumi-1 cells were pre-treated with DMSO,
125 nM, and 250 nM JQ1 for 2 days, and theMCL1
selective inhibitor A1210477 (A121) was added to
cell culture for another 6 hr before Annexin V
(AnnV) and propidium iodide (PI) staining.
Apoptotic cell population was detected by AnnV
positivity and the absence of PI staining. Data are
mean ± SEM (n = 4).
See also Figure S7.reduced 1 hr after BET inhibitor treatment, indicating that
MIR223,MIR29B2, andMIR29C are direct targets of BET inhib-
itors (Figures 6D and 6E).
Inhibition of BET Proteins Sensitizes Cells to MCL1
Inhibition
BET-inhibitor-mediated loss of expression of MIR29B2 and
MIR29C was of special interest, because our PRO-seq analysis
identified MCL1 as transcriptionally activated by BET inhibitors
(Figures S1C, S7A, and S7B). Expression of MCL1 would be ex-
pected to counterbalance the loss of BCL2 expression to sup-
press apoptosis. PRO-seq analysis of the AML patient sample
confirmed the reduction ofMIR29B2 andMIR29C in AML blasts
and the activation of MCL1 transcription (Figures 7A and 7B).
When we analyzed protein levels of E2F1 and MCL1, E2F1 was
only slightly increased at early times by JQ1, whereas MCL1
was upregulated within 3 hr treatment of BET inhibitors (Figures
7C and 7D). Thus, at early time points after BET inhibitor addition,
the effects are more likely due to increased transcription.
Consistent with Kasumi-1 cells being arrested in the G0/G1
phase by BET inhibitors (Figure S1A; Y.Z., T.M. Heaster,2012 Cell Reports 16, 2003–2016, August 16, 2016K.R.S., M.C. Skala, M.R.S., and S.W.H.,
unpublished data), E2F1 protein levels
subsided at 48–72 hr after BET inhibitor
addition (Figure 7C). In contrast, the upre-
gulation of MCL1 was sustained at higher
levels throughout the entire 3-day treat-
ment (Figure 7D). This was true not only
in Kasumi-1 cells, but in other cell types
such as MOLM-13 that also showed
less cell death, whereas MV4-11 failed
to upregulate MCL1 and the cells werekilled by JQ1 (Figure 7E). The induction of MCL1 provides a
possible mechanism of resistance to cell death even in the
face of declining BCL2 levels. Therefore, we tested the com-
bined effects of inhibiting BET proteins and MCL1. Whereas
Kasumi-1 cells were not overtly sensitive to A1210477, a selec-
tiveMCL1 inhibitor (Leverson et al., 2015), pretreating these cells
with JQ1 to reduce the levels of BCL2 sensitized cells to the ef-
fects of the MCL1-selective compound and triggered apoptosis
(Figure 7F). Therefore, transcriptional changes of MIR29C,
MIR29B2, MCL1, and KIT can be used to monitor patient out-
comes after BET inhibitor treatment and provide molecular basis
for combination therapy with MCL1 inhibitors.
DISCUSSION
While there is justifiable excitement about the therapeutic efficacy
of BET inhibitors in AML, only a small portion of the cell types
tested was affected by these compounds, and in most cases it
is unclear what causes sensitivity or resistance (Chapuy et al.,
2013;Delmoreetal., 2011;Filippakopoulosetal., 2010;Lockwood
et al., 2012;Ott et al., 2012; Zuber et al., 2011). PRO-seq creates a
high-resolution and high-sensitivity map of all active RNA poly-
merases and provides directionality of transcription not available
using ChIP-seq (Kwak et al., 2013). This analysis not only showed
a rapid loss of RNA polymerase elongation atMYC but also iden-
tified an eRNA produced by a sub-enhancer within the MYC su-
per-enhancer that was affected by BET inhibitors. Moreover,
PRO-seq analysis identified KIT as a transcriptional target of
BET inhibitors. This receptor tyrosine kinase is expressed in
80% of AML and is activated by mutations in 8% of AML, and
activated KIT is a cooperating mutation in up to 48% of t(8;21)
AML (Forbes et al., 2015; Ikeda et al., 1991; Paschka et al.,
2006; Wang et al., 2005). This suppression of KIT expression by
BET inhibitors provided increased sensitivity to inhibitors of KIT
(Figure 2E). Thus, regulation of KIT provides rationale for the clin-
ical use of BET inhibitors in KIT mutated or amplified AML, and it
could be of use in many other types of AML that express KIT. In
this regard, it is noteworthy that KIT is activated or amplified in
prostate, breast, colon, gastric cancer, as well as other solid can-
cers, which might indicate the utility of BET inhibitors in many
types of cancer (Cerami et al., 2012; Gao et al., 2013).
In addition to KIT, we noted many other genes that are
involved in hematopoietic malignancies displayed a gain of pro-
moter-proximal pausing or impaired elongation in Kasumi-1
cells treated with BET inhibitors. Most notable were a group
of genes that regulate transcriptional elongation including
MLLT1 (ENL), MLLT3 (AF9), MLLT6 (AF17), MLLT10 (AF10),
ELL, MLL, Cyclin T2 (CCNT2, a component of P-TEFb), BRD2,
WDR5, and DOT1L. This might suggest that there is a feedback
loop in which BET proteins regulate components of the super
elongation complex. We also noted that multiple members of
the mediator complex (MED12, MED20, MED24, MED25, and
MED30) were affected by BET inhibitors, as were the chromatin
remodeling factors INO80, INO80D, CBP, GCN5 (KAT2A),
and KAT6B. This implies that BET inhibitors have even more
dramatic effects the longer that the cells are exposed to the
compound. It also highlights specific potential roles for BET
inhibitors in AML.
BRD4 is preferentially enriched at enhancers and super-en-
hancers, and much attention has focused on the selective effect
of BET inhibitors on super-enhancer-regulated genes (Chapuy
et al., 2013; Love´n et al., 2013). We were able to use the diver-
gent transcription that is associated with transcription initiation
to identify defined transcriptional start sites within active en-
hancers and super-enhancers that were affected by BET inhibi-
tors, as well as identify eRNAs. While the mechanism of action of
BET proteins is typically envisioned to be due to enhancers loop-
ing to promoters to stimulate transcriptional elongation through
BET proteins contacting P-TEFb, when coupled with recent
work on the architecture of enhancers (Core et al., 2014), our
study suggests that generation of functional eRNAs is an attrac-
tive model for how enhancers regulate tissue-specific gene
expression. If eRNAs expressed at an enhancer regulate elonga-
tion at promoters, one might expect that the effect of BET inhib-
itors on eRNA expression would precede effects at promoters.
However, PRO-seq at just 15 min after BET inhibitor addition
was not able to temporally separate the effect of BET inhibitors
at the MYC super-enhancer from MYC mRNA production (data
not shown), leaving open the question of how enhancers functionto control tissue-specific gene expression and the contribution
of BET family members to the communication between en-
hancers and promoters.
Amajor advantage of PRO-seq is that it allows the assessment
of rapid changes in transcription from all RNA polymerases and
all regions of the genome at one time, including microRNAs.
While there is rapid loss of MYC expression in cells treated
with BET inhibitors (Chapuy et al., 2013; Delmore et al., 2011;
Ott et al., 2012; Zuber et al., 2011), the loss ofMIR223 transcrip-
tion, which regulates E2F1, could force some tumor cells to
continue to cycle. Indeed, we noted that E2F1 levels only
declined when the cells entered into a G0/G1 arrest at later
time points (Figure 7). Likewise, the loss of transcription of the
pri-microRNA for MIR29B2 and MIR29C, which targets the
anti-apoptotic gene MCL1, likely contributed to the accumula-
tion of MCL1 at later time points. While most genes were
repressed by BET inhibitors, these compounds stimulated the
transcription of MCL1 (Figure S1). Given that BRD4 associates
with the MCL1 promoter (data not shown) (Love´n et al., 2013),
one can speculate that BRD4 acts to maintain the transcription
of MCL1 under normal conditions, but the absence of BRD4
upon BET inhibitor treatment allows MCL1 transactivation by
other TFs that act through different mechanisms. When coupled
with the loss ofMIR29B2 andMIR29C, MCL1 induction likely al-
lows cells to resist apoptosis. The development of selective
MCL1 inhibitors that can be used in combination with BET inhib-
itors, which suppress KIT, MYC, and BCL2 expression, may
prove to be a potent combination for attacking KIT-positive
AML in the clinic.
EXPERIMENTAL PROCEDURES
PRO-Seq Library Preparation and Data Analysis
Nuclear run-on assays were performed and sequencing libraries were con-
structed as described in the Supplemental Experimental Procedures (Kwak
et al., 2013). Libraries were submitted to the Vanderbilt Technologies for
Advanced Genomics (VANTAGE) for sequencing. Pre-processed reads
were aligned to the human genome hg19 (downloaded from UCSC) using
Bowtie2 (v.2.2.4) (Langmead and Salzberg, 2012). See Supplemental Exper-
imental Procedures for additional methods and statistical and informatics
analysis.
RNA-Seq
PolyA+ RNA was enriched for library preparation and submitted to VANTAGE
for RNA sequencing. Pre-processed reads were aligned to the human tran-
scriptome hg19 (downloaded from UCSC) using TopHat (v.2.0.10) (Kim
et al., 2013). See Supplemental Experimental Procedures for statistical and
informatics analysis.
Flow Cytometry for KIT Expression
Cells were seeded at 0.2 3 106/ml and treated with DMSO or 250 nM JQ1 for
24, 48, and 72 hr. 0.5 3 106 cells were collected at each time point, washed
with cold PBS, and stained with antibodies against KIT (catalog no. 313204,
BioLegend) at 4C for 15 min before flow cytometry. All flow cytometry figures
were generated using Flowjo.
Assessment of Apoptosis
Kasumi-1 cells were seeded at 0.2 3 106/ml and immediately treated with
DMSO, 125 nM JQ1, and 250 nM JQ1 for 2 days. Then increasing doses of
A1210477 were added to the pre-treated cells for an additional 6 hr. Apoptosis
was analyzed using a FITC-AnnexinV/PI Apoptosis Detection kit (catalog no.
556547, BD PharMingen).Cell Reports 16, 2003–2016, August 16, 2016 2013
ChIP Assays
Kasumi-1 cells were seeded at 0.5 3 106/ml at the day of experiment, treated
with DMSO, 250 nM JQ1, and 125 nM MS417 for 1 hr. DNA and protein was
crosslinked with 1% formaldehyde at room temperature for 10min, and cross-
linking was terminated by 125 mM glycine. Crosslinked cells were washed
twice with cold PBS, lysed with 1% SDS lysis buffer, and sonicated. 100 ml
of sonicated chromatin was transferred to 900 ml cold dilution buffer, BRD4
antibody (Bethyl Laboratories) and protein G magnetic beads were added,
and reactions were incubated at 4C overnight. Immunoprecipitated protein
and DNA complexes were washed, and crosslinking was reversed before
DNA isolation. 4 ml of DNA was used in each quantitative PCR to assess
BRD4 enrichment. Data were calculated relative to inputs and a transcription-
ally inactive region for normalization and background reduction.
Statistical Analyses
The significance of pausing index change for each gene upon treatment
was evaluated using Fisher’s exact test followed by multiple testing adjust-
ment. Wilcoxon signed-rank test was used for paired comparisons of RNA po-
lymerase pausing indices between two treatments. p values or FDR < 0.05
were considered as statistically significant. For quantifications of apoptosis
and BRD4 binding, results were presented as mean ± SEM. Statistical ana-
lyses were also provided in each corresponding figure legend. See Supple-
mental Experimental Procedures for additional statistical and informatics
analysis.
Supplemental Experimental Procedures
A more robust and detailed description of the methods used and associated
references are listed in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The accession number for the PRO-seq, RNA-seq, and ChIP-exo data is GEO:
GSE83660.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2016.07.032.
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